Homocystinuria Cell Models for Research

Homocystinuria is a rare inherited metabolic disorder characterized by elevated homocysteine levels in blood and urine. The most common form is classic homocystinuria caused by cystathionine beta-synthase (CBS) deficiency, with an estimated global prevalence of 1 in 200,000 to 1 in 335,000 (WHO, 2023). Other forms include methylenetetrahydrofolate reductase (MTHFR) deficiency and defects in cobalamin metabolism. Clinical manifestations include ectopia lentis, skeletal abnormalities (e.g., marfanoid habitus), thromboembolism, and intellectual disability. Without treatment, complications can be severe and life-threatening. Early diagnosis and management (e.g., vitamin B6, betaine, dietary restriction) improve outcomes, but many patients remain at risk for vascular events. The disease serves as a model for understanding homocysteine metabolism and its impact on vascular and neurological systems.

Homocystinuria is an ideal model for studying metabolic pathways, enzyme function, and gene-environment interactions. The disease is monogenic, making it amenable to genetic manipulation. Public datasets, such as those from ClinVar and the Human Gene Mutation Database (HGMD), provide extensive variant information. Open questions include the molecular mechanisms linking hyperhomocysteinemia to thrombosis and connective tissue abnormalities, and the development of targeted therapies. Gene-edited cell models enable functional studies of specific CBS or MTHFR mutations, allowing researchers to dissect genotype-phenotype correlations and test novel therapeutic approaches.

Although homocystinuria is not a cancer, the pathways involved are relevant to cellular stress and proliferation. The major pathways include:

• • Transsulfuration Pathway: CBS converts homocysteine to cystathionine, which is further metabolized to cysteine. Deficiency leads to homocysteine accumulation.
• • Remethylation Pathway: MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for homocysteine remethylation to methionine. Deficiency impairs this process.
• • Folate and Vitamin B12 Metabolism: Defects in cobalamin metabolism (e.g., CblC, CblE, CblG) also cause homocystinuria by affecting methionine synthase activity.
• • Oxidative Stress and Endothelial Dysfunction: Elevated homocysteine leads to oxidative stress, which damages endothelial cells and promotes thrombosis.

Data from ClinVar and HGMD.

Elevated homocysteine affects multiple signaling networks:

• • Endothelial Nitric Oxide Synthase (eNOS): Homocysteine inhibits eNOS, reducing nitric oxide production and causing endothelial dysfunction.
• • Protein Kinase C (PKC): Homocysteine activates PKC, leading to oxidative stress and inflammation.
• • NF-κB Pathway: Homocysteine activates NF-κB, promoting inflammatory cytokine expression.
• • Extracellular Matrix Remodeling: Homocysteine upregulates matrix metalloproteinases (MMPs), contributing to connective tissue degradation.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) offer a more physiologically relevant model, recapitulating tissue-specific metabolism and allowing long-term culture.

• • CBS Knockout Mice: Global CBS knockout mice exhibit severe hyperhomocysteinemia, hepatic steatosis, and skeletal abnormalities. They are used to study disease mechanisms and test therapies.
• • MTHFR Knockout Mice: These mice show mild hyperhomocysteinemia and vascular dysfunction.
• • Induced Models: Administration of high-methionine diets or homocysteine injection can induce hyperhomocysteinemia in wild-type mice.
• • Patient-Derived Xenografts (PDX): Not applicable for metabolic disorders, but iPSC-derived organoids can be transplanted into mice for in vivo studies.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific CBS or MTHFR mutations. For example:

• • CBS Knockout Cell Lines: Complete loss of CBS function mimics severe homocystinuria. These lines are useful for studying the effects of homocysteine accumulation on cellular pathways.
• • Point-Mutation Knock-In Lines: Introduction of specific patient mutations (e.g., p.I278T) allows genotype-phenotype correlation and drug testing.
• • Reporter Lines: CBS promoter-driven fluorescent reporters can be used to monitor gene expression in high-throughput screens.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent, validated tools. These models are essential for drug discovery, target validation, and functional genomics.

Gene-edited cell lines are used to validate the function of CBS and MTHFR variants. For example, introducing a specific CBS mutation into a wild-type cell line and measuring enzyme activity and homocysteine levels confirms the pathogenicity of the variant. Knockout lines can be used to identify synthetic lethal partners or downstream effectors via CRISPR screens.

Isogenic pairs (wild-type vs. mutant) are ideal for drug screening. For homocystinuria, compounds that reduce homocysteine levels (e.g., betaine, vitamin B6) can be tested for efficacy in CBS knockout lines. Additionally, drug resistance mechanisms can be studied by exposing cells to increasing concentrations of a therapeutic and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal only in CBS-deficient cells. These genes may serve as novel therapeutic targets or biomarkers. Additionally, proteomic and metabolomic profiling of gene-edited cells can identify novel biomarkers for disease monitoring.